Subjects and lessons to explore.

Law

Cell Biology · Advanced: Cell Signaling

04 — RTKs and the Ras-MAPK Pathway

5 min read
Report an error
Want it in plain words first? Jump to Eli explains — the same idea, no jargon.
On this page 5 sections
  1. Why this matters
  2. The college version
  3. Eli explains
  4. Key takeaway
  5. Study tools

Why this matters

The Ras-MAPK pathway is one of the most important signaling cascades in cell biology. It controls cell proliferation, differentiation, and survival. Mutations in pathway components — particularly Ras — are found in approximately 30% of all human cancers. Understanding this pathway is essential for both basic cell biology and cancer therapeutics.

The college version

Core Explanation

RTK Activation

Receptor tyrosine kinases (RTKs) are single-pass transmembrane proteins (~58 in humans) with an extracellular ligand-binding domain and an intracellular tyrosine kinase domain. Key steps:

  1. Ligand binding (e.g., EGF, insulin, FGF, PDGF) induces receptor dimerization or conformational reorganization. Important: Not all RTKs use identical dimerization mechanisms — some bind ligand as pre-formed dimers that undergo conformational change upon ligand binding (e.g., the insulin receptor exists as a disulfide-linked dimer and undergoes structural rearrangement upon insulin binding).
  1. Trans-autophosphorylation: Each receptor monomer's kinase domain phosphorylates specific tyrosine residues on the other monomer's intracellular tail. This creates phosphotyrosine docking sites.
  1. Phosphotyrosines serve as recruitment platforms for intracellular signaling proteins containing SH2 (Src homology 2) or PTB (phosphotyrosine-binding) domains. These domains recognize specific phosphotyrosine-containing peptide sequences, providing binding specificity. Different RTKs phosphorylate different tyrosine residues, recruiting different complements of SH2/PTB proteins — this is how different growth factors trigger different responses through structurally similar receptors.

The Ras-MAPK Kinase Cascade

Ras is a small GTPase (~21 kDa) — a molecular switch, NOT a kinase. It does not phosphorylate anything. Ras is active when GTP-bound and inactive when GDP-bound.

Signal relay from RTK to Ras:

  1. Activated RTK creates phosphotyrosine docking sites
  2. Adaptor protein Grb2 (SH2 domain) binds specific phosphotyrosine on the RTK
  3. Grb2, via its SH3 domains, recruits Sos (Son of Sevenless), a GEF (guanine nucleotide exchange factor)
  4. Sos is brought into proximity with membrane-anchored Ras
  5. Sos catalyzes GDP→GTP exchange on Ras → Ras-GTP is now active

The three-tiered MAP kinase cascade:

  1. Ras-GTP recruits and activates Raf (MAP kinase kinase kinase, MAP3K) at the plasma membrane
  2. Raf phosphorylates and activates MEK (MAP kinase kinase, MAP2K) on two serine residues
  3. MEK phosphorylates and activates ERK (MAP kinase, MAPK — the effector) on threonine and tyrosine (dual-specificity kinase)
  4. Activated ERK dimerizes and translocates to the nucleus
  5. In the nucleus, ERK phosphorylates transcription factors (Elk-1, c-Fos, c-Jun, c-Myc) → changes in gene expression → cell proliferation, differentiation, survival

Signal amplification: Each activated Raf can phosphorylate many MEK molecules; each MEK can phosphorylate many ERK; each ERK can phosphorylate many targets. A single activated RTK can influence expression of hundreds of genes.

Regulation and Termination

  • Ras intrinsic GTPase activity: Ras slowly hydrolyzes GTP→GDP (off-switch). This is accelerated ~10⁵-fold by GAPs (GTPase-activating proteins, e.g., NF1 neurofibromin).
  • Phosphatases: MAP kinase phosphatases (MKPs) dephosphorylate and inactivate ERK.
  • Negative feedback: Active ERK phosphorylates Sos, reducing its affinity for Grb2 — the pathway inhibits its own upstream activator.

Cancer Relevance

Mutations that lock Ras in the GTP-bound state are among the most common oncogenic mutations:

  • K-Ras G12V/G12D/G13D: Glycine-12 mutations block GTP hydrolysis (resistant to GAPs). Ras remains constitutively active → continuous proliferation signaling. Found in pancreatic (~90%), colorectal (~45%), and lung (~35%) cancers.
  • B-Raf V600E: Constitutively active Raf kinase. Found in ~50% of melanomas. Targeted by vemurafenib.
  • NF1 loss: Loss of Ras-GAP → elevated Ras-GTP. Neurofibromatosis type 1.

Common Misconceptions

  • Wrong: "Ras is a kinase." Correct: Ras is a small GTPase — a molecular switch. Raf, MEK, and ERK are the kinases.
  • Wrong: "All RTKs activate through the same mechanism." Correct: Dimerization mechanisms vary; the insulin receptor is a pre-formed dimer that undergoes conformational change.
  • Wrong: "The Ras pathway is simple and linear." Correct: Extensive crosstalk, feedback loops, and scaffolding proteins create complex signal processing.
Eli, the EliExplains learning guide

Eli explains

The same idea, in plain words

Explain it like I’m 10

RTKs are growth signal receivers on the cell surface. When a growth factor lands on the receptor, two receptors pair up and tag each other with phosphate groups — like two friends stamping each other's hands. These phosphate stamps create docking stations for relay proteins inside the cell.

The first relay protein activates Ras — think of Ras as a tiny molecular timer that flips from "off" (GDP) to "on" (GTP). When Ras is on, it starts a chain reaction: Ras wakes up Raf, Raf wakes up MEK, MEK wakes up ERK. ERK is the final messenger — it runs straight to the nucleus and says "grow and divide!" One growth signal outside can trigger hundreds of cells to start growing inside.

Here is the problem: mutant Ras gets stuck in the "on" position forever. The timer never runs out. It keeps screaming "grow!" even when the cell should stop. That is why Ras mutations are found in one-third of all human cancers — a broken switch that cannot turn off.

Key takeaways

  • High Yield: Ras is a small GTPase molecular switch — it is NOT a kinase.
  • High Yield: The MAPK cascade is a three-tiered kinase cascade: MAP3K (Raf) → MAP2K (MEK) → MAPK (ERK).
  • High Yield: Ras G12V/G12D mutations impair GTP hydrolysis → constitutive Ras activation → cancer.
  • High Yield: Adaptor proteins (Grb2) and GEFs (Sos) link activated RTKs to Ras; they have no enzymatic activity themselves.
  • Ras is often mentioned alongside kinases in the MAPK pathway. Is Ras itself a kinase? What is its actual biochemical function?
  • A researcher treats cells with a MEK inhibitor. Predict the effect on ERK phosphorylation and on Ras-GTP levels. Explain your reasoning.
  • Why are glycine-12 mutations in Ras oncogenic? What specific biochemical step do they impair?
  • Ras is NOT a kinase. It is a small GTPase — a molecular switch that binds GTP (active) or GDP (inactive). Its role is to recruit and activate Raf (the first kinase in the cascade). Ras has no phosphorylation activity.
  • ERK phosphorylation will decrease (MEK is the direct upstream activator of ERK). Ras-GTP levels will be unaffected or may increase (due to loss of ERK-mediated negative feedback on Sos). The inhibitor acts downstream of Ras.
  • Glycine-12 is located in the GTP-binding pocket (P-loop). G12V/G12D mutations sterically block access of the catalytic water molecule and prevent GAP-stimulated GTP hydrolysis. Ras cannot convert GTP→GDP efficiently, remaining locked in the active GTP-bound state.

Keep learning

Ready to build on this? Continue to the next lesson.

Study tools & related lessonsYou’ll learn to · Related

You’ll learn to

  • Describe RTK activation (ligand binding, dimerization, trans-autophosphorylation)
  • Explain SH2/PTB domain-mediated adaptor recruitment
  • Trace the Ras → Raf → MEK → ERK kinase cascade
  • Connect Ras mutations to cancer
  • Explain why Ras is a GTPase switch, not a kinase

Educational content only. It is not medical, legal or professional advice. Found an error? Tell us.